Effect of Sidaguri (Sida Rhombifolia L) on Womac Score Assessment in Osteoarthritis Patients

Abstract

Introduction : WOMAC scoring is one of the tools to assess the effectivity of therapy in osteoarthritis (OA) patients. The efficacy is proven if there is a decrease in WOMAC score after given therapy. Pain is the major complaint of OA patients, and it is usually connected with in�����ammatory process. NSAIDs are the most common therapy given in OA to reduce pain. Sidaguri (Sida rhombifolia L) is one of the medicinal plants which had anti-in�����ammatory activities by inhibiting nitric oxide (NO). Method : a double blind randomized clinical trial was conducted in Adam Malik Hospital in september-november 2017. OA patients were assessed for WOMAC score and screened for liver and renal function before given treatment. They were randomized to receive combination of Sidaguri extract and meloxicam or meloxicam and placebo in a double-blind technique. Each group involved 25 patients who received one month therapy. At the end of therapy, all patients were rechecked their liver and renal function, and also reassessed the WOMAC score. Data were statisctically analyzed. Result : After one month therapy, we redid the WOMAC assessment to all the patients . The total score of WOMAC after given Sidagurimeloxicam is 7,2 (3,12-17,7)%, while the meloxicam-placebo is 36,4(22-71,8)% (p=0,0001). Conclusion : Sidaguri extract can be given as an effective alternative therapy in osteoarthritis patients.